Edelman BioScience managing director David Noble shown the door

Edelman has made the managing director of its BioScience division redundant as part of a 'restructure'.

Now overseeing BioScience division: Steven Spurr
Now overseeing BioScience division: Steven Spurr

David Noble leaves the agency this month following a three-week consultation process. He had been heading the agency’s specialist medical communications business unit for more than three years.

The division specialises in publication planning, advisory board management, meetings and symposia,
clinical trial recruitment/retention and market access support.

Responsibility for the division will be passed to Steven Spurr, who heads Edelman’s 40-strong ethical healthcare division.

Edelman UK CEO Robert Phillips said the decision had been made to make Noble’s position redundant as part of a management restructure.

‘The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising
internally to have more fluent interaction between the teams,’ said Phillips.

Spurr took over as head of the UK healthcare team last year after European healthcare managing director Mike Kan was made redundant.

Noble previously worked as managing director of Hill & Knowlton’s healthcare strategic consulting and medical knowledge group before joining Edelman in 2006.

Edelman’s healthcare team moved down to the third spot in this year’s PRWeek Healthcare League tables from the second slot last year.

The division had an income of £6,815,000 in 2009, up from £6,302,000 in 2008.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in